Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer
|ClinicalTrials.gov Identifier: NCT00908739|
Recruitment Status : Withdrawn (PI left)
First Posted : May 27, 2009
Last Update Posted : September 30, 2015
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at tumor tissue samples from patients who have undergone surgery for localized kidney cancer.
|Condition or disease||Intervention/treatment|
|Kidney Cancer||Genetic: gene expression analysis Other: immunohistochemistry staining method Other: laboratory biomarker analysis|
- To identify consistent patterns of VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity as predictive factors in the development of aggressive tumor behavior in tumor tissue samples from patients with localized clear cell renal cell carcinoma.
OUTLINE: Previously collected tumor tissue samples are examined by immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity). Samples are compared to positive tissue controls (i.e., VEGF- tonsil; E- cadherin-normal breast or endometrium; MMP2- placenta) and a negative control (i.e., isotype matched normal serum) to identify consistent patterns of expression/activity of these factors. Levels of expression are quantified as 5-level scores (0 to 4 scale) and differences between any two areas of a tumor are analyzed.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Observational Model:||Case Control|
|Official Title:||Assessment of Patterns of Expression of VEGF, Matrix Metalloproteinase 2, 9 Activity, E-Cadherin Regulation and CA-9 Activity as Predictors of Aggressive Renal Cell Carcinoma Behavior|
|Study Start Date :||May 2008|
|Actual Primary Completion Date :||September 2008|
Genetic: gene expression analysis
- Relative patterns of expression/activity of five different growth factors/enzymes inherently related to the development of metastatic renal cell carcinoma behavior
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00908739
|Principal Investigator:||David A. Levy, MD||Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center|